Menu
GWAS Study

Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets.

Wain LV, Shrine N, Artigas MS et al.

28166213 PubMed ID
GWAS Study Type
144318 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WL
Wain LV
SN
Shrine N
AM
Artigas MS
EA
Erzurumluoglu AM
NB
Noyvert B
BL
Bossini-Castillo L
OM
Obeidat M
HA
Henry AP
PM
Portelli MA
HR
Hall RJ
BC
Billington CK
RT
Rimington TL
FA
Fenech AG
JC
John C
BT
Blake T
JV
Jackson VE
AR
Allen RJ
PB
Prins BP
CA
Campbell A
PD
Porteous DJ
JM
Jarvelin MR
WM
Wielscher M
JA
James AL
HJ
Hui J
WN
Wareham NJ
ZJ
Zhao JH
WJ
Wilson JF
JP
Joshi PK
SB
Stubbe B
RR
Rawal R
SH
Schulz H
IM
Imboden M
PN
Probst-Hensch NM
KS
Karrasch S
GC
Gieger C
DI
Deary IJ
HS
Harris SE
MJ
Marten J
RI
Rudan I
ES
Enroth S
GU
Gyllensten U
KS
Kerr SM
PO
Polasek O
KM
Kähönen M
SI
Surakka I
VV
Vitart V
HC
Hayward C
LT
Lehtimäki T
RO
Raitakari OT
ED
Evans DM
HA
Henderson AJ
PC
Pennell CE
WC
Wang CA
SP
Sly PD
WE
Wan ES
BR
Busch R
HB
Hobbs BD
LA
Litonjua AA
SD
Sparrow DW
GA
Gulsvik A
BP
Bakke PS
CJ
Crapo JD
BT
Beaty TH
HN
Hansel NN
MR
Mathias RA
RI
Ruczinski I
BK
Barnes KC
BY
Bossé Y
JP
Joubert P
VD
van den Berge M
BC
Brandsma CA
PP
Paré PD
SD
Sin DD
ND
Nickle DC
HK
Hao K
GO
Gottesman O
DF
Dewey FE
BS
Bruse SE
CD
Carey DJ
KH
Kirchner HL
JS
Jonsson S
TG
Thorleifsson G
JI
Jonsdottir I
GT
Gislason T
SK
Stefansson K
SC
Schurmann C
NG
Nadkarni G
BE
Bottinger EP
LR
Loos RJ
WR
Walters RG
CZ
Chen Z
MI
Millwood IY
VJ
Vaucher J
KO
Kurmi OP
LL
Li L
HA
Hansell AL
BC
Brightling C
ZE
Zeggini E
CM
Cho MH
SE
Silverman EK
SI
Sayers I
TG
Trynka G
MA
Morris AP
SD
Strachan DP
HI
Hall IP
TM
Tobin MD
Chapter II

Abstract

Summary of the research findings

Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratio per 1 s.d. of the risk score (∼6 alleles) (95% confidence interval) = 1.24 (1.20-1.27), P = 5.05 × 10-49), and we observed a 3.7-fold difference in COPD risk between individuals in the highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in genes for development, elastic fibers and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications.

48,943 European ancestry individuals.

Chapter III

Study Statistics

Key metrics and study information

144318
Total Participants
GWAS
Study Type
Yes
Replicated
57,176 European ancestry individuals, 38,199 individuals.
Replication Participants
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.